However, despite the potential importance of IFN treatment in the initial days of infection, its administration during the inflammatory and severe phases of SARS-CoV-2 infection could potentially exacerbate the condition, potentially leading to uncontrolled inflammatory responses and harmful effects (31, –, 33). Here, IFNA1 is linked to infection.